JP2019528279A - キナーゼ阻害物質化合物、組成物、及びがんの治療方法 - Google Patents

キナーゼ阻害物質化合物、組成物、及びがんの治療方法 Download PDF

Info

Publication number
JP2019528279A
JP2019528279A JP2019508942A JP2019508942A JP2019528279A JP 2019528279 A JP2019528279 A JP 2019528279A JP 2019508942 A JP2019508942 A JP 2019508942A JP 2019508942 A JP2019508942 A JP 2019508942A JP 2019528279 A JP2019528279 A JP 2019528279A
Authority
JP
Japan
Prior art keywords
alkyl
mmol
compound
halogen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019508942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528279A5 (enExample
Inventor
アーヴィン シー． ダー
アーヴィン シー． ダー
ロス エル． ケイガン
ロス エル． ケイガン
アレックス ピー． スコープトン
アレックス ピー． スコープトン
マサヒロ ソノシタ
マサヒロ ソノシタ
Original Assignee
アイカーン スクール オブ メディシン アット マウント サイナイ
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディシン アット マウント サイナイ, アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical アイカーン スクール オブ メディシン アット マウント サイナイ
Publication of JP2019528279A publication Critical patent/JP2019528279A/ja
Publication of JP2019528279A5 publication Critical patent/JP2019528279A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019508942A 2016-08-17 2017-08-17 キナーゼ阻害物質化合物、組成物、及びがんの治療方法 Pending JP2019528279A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376138P 2016-08-17 2016-08-17
US62/376,138 2016-08-17
PCT/US2017/047383 WO2018035346A1 (en) 2016-08-17 2017-08-17 Kinase inhibitor compounds, compositions, and methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2019528279A true JP2019528279A (ja) 2019-10-10
JP2019528279A5 JP2019528279A5 (enExample) 2020-09-17

Family

ID=61197083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508942A Pending JP2019528279A (ja) 2016-08-17 2017-08-17 キナーゼ阻害物質化合物、組成物、及びがんの治療方法

Country Status (6)

Country Link
US (2) US10519113B2 (enExample)
EP (1) EP3500257B1 (enExample)
JP (1) JP2019528279A (enExample)
CN (1) CN110072526A (enExample)
CA (1) CA3034332A1 (enExample)
WO (1) WO2018035346A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220032607A (ko) 2020-02-27 2022-03-15 국립대학법인 홋가이도 다이가쿠 항암제를 스크리닝하는 방법 및 췌장암 치료를 위한 키나아제 억제제의 조합 의약

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440404A (zh) * 2018-05-08 2018-08-24 西安凯伦生物科技有限公司 具有多重激酶抑制作用的抗肿瘤药物及其制备方法和应用
CN111362871B (zh) * 2018-12-25 2022-05-17 北京福元医药股份有限公司 取代的吡啶-2-甲酰胺类化合物及其用途
CN113402456B (zh) * 2020-03-16 2023-03-03 深圳大学 一种抗肿瘤药物以及一种化合物或其药学上可接受的盐在抗肿瘤药物中的应用
BR112022022342A2 (pt) * 2020-05-08 2023-01-03 Georgiamune Llc Moduladores de akt3
US20230404985A1 (en) * 2020-11-02 2023-12-21 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancers having dysregulated wnt signaling pathways
KR102710925B1 (ko) * 2021-06-01 2024-09-27 부산대학교 산학협력단 신규 스퀘어아마이드 유도체 및 이의 용도
WO2025083280A1 (en) * 2023-10-19 2025-04-24 Universitat De Barcelona Sorafenib analogs for use in the treatment of cancer

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526220A (ja) * 1997-12-22 2001-12-18 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
US20030144278A1 (en) * 2001-01-12 2003-07-31 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2006519265A (ja) * 2003-02-28 2006-08-24 バイエル ファーマシューティカルス コーポレーション 癌その他の疾患の治療に有用な新規な二環尿素誘導体
JP2007508238A (ja) * 2003-07-07 2007-04-05 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング マロンアミド誘導体
JP2007511203A (ja) * 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
US20090012091A1 (en) * 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
JP2009521449A (ja) * 2005-12-21 2009-06-04 バイエル・ヘルスケア・アクチェンゲゼルシャフト 癌および他の障害の処置に有用な置換ピリミジン誘導体
CN101723890A (zh) * 2008-10-10 2010-06-09 中国科学院成都生物研究所 芳基硫脲及其制备方法和用途
JP2011063516A (ja) * 2009-09-15 2011-03-31 Daiichi Sankyo Co Ltd アミド誘導体
WO2011046991A2 (en) * 2009-10-15 2011-04-21 Gilead Connecticut, Inc. Certain substituted ureas as modulators of kinase activity
WO2012112570A1 (en) * 2011-02-14 2012-08-23 The Regents Of The University Of California SORAFENIB DERIVATIVES AS sEH INHIBITORS
JP2014527043A (ja) * 2011-08-03 2014-10-09 ナショナル タイワン ユニバーシティ Ｓｒｃホモロジー２プロテインチロシンホスファターゼ−１を含むアゴニスト及びその治療方法
WO2015051149A1 (en) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof
US20150132408A1 (en) * 2012-07-06 2015-05-14 The Regents Of The University Of California Sorafenib derivatives as p21 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE529406T1 (de) * 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
AU2003257991A1 (en) 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
JP4594925B2 (ja) * 2003-02-28 2010-12-08 ニッポネックス インコーポレイテッド 増殖亢進性、血管新生性及び炎症性疾患の治療に有用な２−オキソ−１，３，５−パーヒドロトリアザピン誘導体
HRP20060073B1 (hr) * 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
WO2006026501A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
RU2009114745A (ru) * 2006-09-19 2010-10-27 Новартис АГ (CH) Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
US9090617B1 (en) * 2011-08-03 2015-07-28 National Taiwan University Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
CN103508961B (zh) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526220A (ja) * 1997-12-22 2001-12-18 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
US20030144278A1 (en) * 2001-01-12 2003-07-31 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2006519265A (ja) * 2003-02-28 2006-08-24 バイエル ファーマシューティカルス コーポレーション 癌その他の疾患の治療に有用な新規な二環尿素誘導体
JP2007511203A (ja) * 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
JP2007508238A (ja) * 2003-07-07 2007-04-05 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング マロンアミド誘導体
JP2009521449A (ja) * 2005-12-21 2009-06-04 バイエル・ヘルスケア・アクチェンゲゼルシャフト 癌および他の障害の処置に有用な置換ピリミジン誘導体
US20090012091A1 (en) * 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
CN101723890A (zh) * 2008-10-10 2010-06-09 中国科学院成都生物研究所 芳基硫脲及其制备方法和用途
JP2011063516A (ja) * 2009-09-15 2011-03-31 Daiichi Sankyo Co Ltd アミド誘導体
WO2011046991A2 (en) * 2009-10-15 2011-04-21 Gilead Connecticut, Inc. Certain substituted ureas as modulators of kinase activity
WO2012112570A1 (en) * 2011-02-14 2012-08-23 The Regents Of The University Of California SORAFENIB DERIVATIVES AS sEH INHIBITORS
JP2014527043A (ja) * 2011-08-03 2014-10-09 ナショナル タイワン ユニバーシティ Ｓｒｃホモロジー２プロテインチロシンホスファターゼ−１を含むアゴニスト及びその治療方法
US20150132408A1 (en) * 2012-07-06 2015-05-14 The Regents Of The University Of California Sorafenib derivatives as p21 inhibitors
WO2015051149A1 (en) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, JPN6022024470, 2013, pages 3732 - 3737, ISSN: 0005163291 *
LI, GUO-BO 他: "LEADOPT: An automatic tool for structure-based lead optimization, and its application in structural", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 93, JPN6021028198, 2015, pages 523 - 538, ISSN: 0004800276 *
USHARANI, V. 他: "Synthesis of aryl urea derivatives from aryl amines and aryl isocyanates", ASIAN JOURNAL OF CHEMISTRY, vol. 23(4), JPN6021028193, 2011, pages 1802 - 1806, ISSN: 0004800278 *
ZHANG, LIJUAN 他: "Convenient synthesis of Sorafenib and its derivatives", SYNTHETIC COMMUNICATIONS, vol. 41(21), JPN6021028195, 2011, pages 3140 - 3146, ISSN: 0004800277 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220032607A (ko) 2020-02-27 2022-03-15 국립대학법인 홋가이도 다이가쿠 항암제를 스크리닝하는 방법 및 췌장암 치료를 위한 키나아제 억제제의 조합 의약

Also Published As

Publication number Publication date
US20200325103A1 (en) 2020-10-15
US20190202789A1 (en) 2019-07-04
EP3500257A1 (en) 2019-06-26
US10519113B2 (en) 2019-12-31
WO2018035346A1 (en) 2018-02-22
CA3034332A1 (en) 2018-02-22
EP3500257A4 (en) 2020-01-22
EP3500257B1 (en) 2025-07-02
CN110072526A (zh) 2019-07-30
US11066370B2 (en) 2021-07-20
WO2018035346A8 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
JP2019528279A (ja) キナーゼ阻害物質化合物、組成物、及びがんの治療方法
TWI869913B (zh) 吡啶并[4,3-d]嘧啶化合物
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
CN104903321B (zh) 作为激酶抑制剂的经取代三环苯并咪唑
KR20200011965A (ko) Map4k1의 신규한 억제제
EP4619104A1 (en) Bicyclic heterocycles and their use as wrn inhibitors
KR20190086442A (ko) 피리딘 화합물
PT2125776T (pt) Compostos espiro substituídos como inibidores da angiogénese
EA034235B1 (ru) Новые композиции, их использование и способы получения
WO2016169504A1 (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
EP2799437A1 (en) Quinoline and cinnoline compounds and use thereof
JP6380777B2 (ja) ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物
JP2020527173A (ja) ヒストン脱アセチル化酵素１および／または２（ｈｄａｃ１−２）の選択的阻害剤としての新規なヘテロアリールアミド誘導体
WO2020224652A1 (zh) 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
CN112457306A (zh) 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
WO2023051302A1 (zh) 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途
CN114805351A (zh) 作为pi3k/mtor抑制剂的带有酰胺基的吡啶基取代的稠合喹啉化合物
US20120108584A1 (en) 2h or 3h-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof
JP2018087173A (ja) 悪性脳腫瘍治療薬
WO2023155900A1 (zh) 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途
US9499552B2 (en) Pyrazolo[1,5-A]pyrimidine derivative and use of anti-tumor thereof
CN113135938B (zh) 取代的大环类酪氨酸激酶抑制剂及其用途
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
HK40010493A (en) Kinase inhibitor compounds, compositions, and methods of treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200807

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231002